Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

1 in 10 Americans Has Used GLP-1 Drugs For Weight Loss, Survey Says

FRIDAY, Aug. 8, 2025 More than 1 in 10 Americans have used a GLP-1 drug for weight loss, a new survey by the RAND research group reveals.About 12 say they ve tr

Could CAR-T Therapy Be a Cure for Lupus? Early Trials Show Promise

FRIDAY, Aug. 8, 2025 Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a spectrum of very different manifestations and variable severity.

AI Chatbots Easily Misled By Fake Medical Info

FRIDAY, Aug. 8, 2025 Ever heard of Casper-Lew Syndrome or Helkand Disease How about black blood cells or renal stormblood rebound echo If not, no worries. These

Verbal Abuse As Damaging As Physical Abuse To Children's Mental Health

FRIDAY, Aug. 8, 2025 Sticks and stones may break my bones, but words will never hurt me. This old saying is just plain wrong, a new study argues.Verbal abuse in

Staying Active Might Slow Parkinson's Progression

FRIDAY, Aug. 8, 2025 Staying active might slow the brain changes associated with Parkinson s disease, a new study says.Parkinson s patients who kept active by w

Sebela Pharmaceuticals Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results

Braintree Laboratories, a part of Sebela Pharmaceuticals and a leading manufacturer of gastroenterology pharmaceutical products, today announced positive toplin

U.S. FDA Granted Fast Track Designation to Dizal’s Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

August 6, 2025 Dizal (SSE 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, a

Lilly's Oral GLP-1, Orforglipron, Delivers Weight Loss of Up To an Average of 27.3 lbs in First of Two Pivotal Phase 3 Trials in Adults with Obesity

Eli Lilly and Company (NYSE LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral gluc

Boehringer and Click Therapeutics’ Investigational Prescription Digital Therapeutic CT-155 Meets Primary Endpoint in CONVOKE Study for Negative Symptoms in Schizophrenia

Boehringer Ingelheim and Click Therapeutics today announced that the pivotal Phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080), an investigational pr

FDA Approves SetPoint Neuroimmune Modulation Device for Rheumatoid Arthritis

existing advanced RA therapies, such as biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs). The SetPoint System is an implantable,

Popular Keywords